Applied DNA Sciences, Inc. (APDN)
USD 0.23
(1.26%)
USD 0.23
(1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.94 Million USD | -18.73% |
| 2022 | -8.37 Million USD | 47.73% |
| 2021 | -16.02 Million USD | -25.57% |
| 2020 | -12.76 Million USD | -47.87% |
| 2019 | -8.63 Million USD | 26.17% |
| 2018 | -11.69 Million USD | 9.05% |
| 2017 | -12.85 Million USD | -5.58% |
| 2016 | -12.17 Million USD | -2.48% |
| 2015 | -11.88 Million USD | 9.07% |
| 2014 | -13.06 Million USD | 26.12% |
| 2013 | -17.68 Million USD | -147.34% |
| 2012 | -7.15 Million USD | 32.0% |
| 2011 | -10.51 Million USD | -32.94% |
| 2010 | -7.9 Million USD | -300.52% |
| 2009 | 3.94 Million USD | 157.98% |
| 2008 | -6.8 Million USD | 48.87% |
| 2007 | -13.3 Million USD | -452.01% |
| 2006 | -2.41 Million USD | 95.42% |
| 2005 | -52.61 Million USD | -171.77% |
| 2004 | -19.35 Million USD | -461.9% |
| 2003 | -3.44 Million USD | -40044.07% |
| 2002 | -8582.00 USD | -50.03% |
| 2001 | -5720.00 USD | -70.54% |
| 2000 | -3354.00 USD | -112.01% |
| 1999 | -1582.00 USD | -149.53% |
| 1998 | -634.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.47 Million USD | -277.94% |
| 2024 Q1 | -1.18 Million USD | 67.07% |
| 2024 Q3 | 1.87 Million USD | 142.05% |
| 2023 Q1 | -3.84 Million USD | -397.16% |
| 2023 FY | -9.94 Million USD | -18.73% |
| 2023 Q3 | -3.09 Million USD | -626.86% |
| 2023 Q2 | 588.34 Thousand USD | 115.31% |
| 2023 Q4 | -3.59 Million USD | -15.89% |
| 2022 Q2 | -1.12 Million USD | 76.12% |
| 2022 Q3 | -1.12 Million USD | 0.29% |
| 2022 Q1 | -4.72 Million USD | -4.67% |
| 2022 FY | -8.37 Million USD | 47.73% |
| 2022 Q4 | -773.06 Thousand USD | 31.24% |
| 2021 FY | -16.02 Million USD | -25.57% |
| 2021 Q1 | -4.8 Million USD | -16.65% |
| 2021 Q2 | -1.51 Million USD | 68.46% |
| 2021 Q3 | -3.44 Million USD | -127.39% |
| 2021 Q4 | -4.51 Million USD | -30.79% |
| 2020 Q2 | -2.95 Million USD | -10.87% |
| 2020 Q1 | -2.66 Million USD | -117.52% |
| 2020 FY | -12.76 Million USD | -47.87% |
| 2020 Q4 | -4.12 Million USD | -25.34% |
| 2020 Q3 | -3.28 Million USD | -11.43% |
| 2019 FY | -8.63 Million USD | 26.17% |
| 2019 Q3 | -1.47 Million USD | 44.99% |
| 2019 Q4 | -1.22 Million USD | 17.17% |
| 2019 Q1 | -3.23 Million USD | 6.93% |
| 2019 Q2 | -2.68 Million USD | 16.93% |
| 2018 Q2 | -2.14 Million USD | 32.59% |
| 2018 Q3 | -2.88 Million USD | -34.55% |
| 2018 Q4 | -3.47 Million USD | -20.35% |
| 2018 Q1 | -3.18 Million USD | -11.53% |
| 2018 FY | -11.69 Million USD | 9.05% |
| 2017 Q4 | -2.85 Million USD | -9.34% |
| 2017 FY | -12.85 Million USD | -5.58% |
| 2017 Q3 | -2.61 Million USD | 23.86% |
| 2017 Q2 | -3.42 Million USD | 13.44% |
| 2017 Q1 | -3.96 Million USD | -64.03% |
| 2016 Q1 | -2.92 Million USD | -489.93% |
| 2016 FY | -12.17 Million USD | -2.48% |
| 2016 Q2 | -3.46 Million USD | -18.5% |
| 2016 Q3 | -3.36 Million USD | 2.9% |
| 2016 Q4 | -2.41 Million USD | 28.27% |
| 2015 Q3 | -1.67 Million USD | 11.39% |
| 2015 Q4 | -496.03 Thousand USD | 70.31% |
| 2015 FY | -11.88 Million USD | 9.07% |
| 2015 Q2 | -1.88 Million USD | 75.91% |
| 2015 Q1 | -7.82 Million USD | -271.82% |
| 2014 Q4 | -2.1 Million USD | -9.72% |
| 2014 FY | -13.06 Million USD | 26.12% |
| 2014 Q1 | -6.29 Million USD | -69.2% |
| 2014 Q2 | -2.75 Million USD | 56.28% |
| 2014 Q3 | -1.91 Million USD | 30.23% |
| 2013 FY | -17.68 Million USD | -147.34% |
| 2013 Q1 | -8.7 Million USD | -392.55% |
| 2013 Q2 | -3.12 Million USD | 64.07% |
| 2013 Q4 | -3.71 Million USD | -74.12% |
| 2013 Q3 | -2.13 Million USD | 31.72% |
| 2012 FY | -7.15 Million USD | 32.0% |
| 2012 Q4 | -1.76 Million USD | -23.62% |
| 2012 Q3 | -1.42 Million USD | 7.4% |
| 2012 Q2 | -1.54 Million USD | 35.94% |
| 2012 Q1 | -2.4 Million USD | 45.44% |
| 2011 Q3 | -2.15 Million USD | 17.07% |
| 2011 Q4 | -4.41 Million USD | -104.98% |
| 2011 FY | -10.51 Million USD | -32.94% |
| 2011 Q1 | -1.34 Million USD | 36.47% |
| 2011 Q2 | -2.59 Million USD | -93.34% |
| 2010 FY | -7.9 Million USD | -300.52% |
| 2010 Q1 | -1.8 Million USD | -25.0% |
| 2010 Q2 | -1.38 Million USD | 23.16% |
| 2010 Q4 | -2.11 Million USD | 18.53% |
| 2010 Q3 | -2.59 Million USD | -86.94% |
| 2009 Q2 | 10.03 Million USD | 402.7% |
| 2009 Q1 | -3.31 Million USD | -82.63% |
| 2009 Q4 | -1.44 Million USD | -8.7% |
| 2009 FY | 3.94 Million USD | 157.98% |
| 2009 Q3 | -1.33 Million USD | -113.26% |
| 2008 Q4 | -1.81 Million USD | -18.78% |
| 2008 Q3 | -1.52 Million USD | 0.0% |
| 2008 Q2 | -1.52 Million USD | 28.32% |
| 2008 Q1 | -2.13 Million USD | 57.95% |
| 2008 FY | -6.8 Million USD | 48.87% |
| 2007 FY | -13.3 Million USD | -452.01% |
| 2007 Q4 | -5.07 Million USD | -380.5% |
| 2007 Q3 | 1.8 Million USD | 119.29% |
| 2007 Q2 | -9.37 Million USD | -1296.0% |
| 2007 Q1 | -671.22 Thousand USD | 88.56% |
| 2006 Q1 | -2.44 Million USD | 88.24% |
| 2006 Q4 | -5.86 Million USD | -104493.16% |
| 2006 Q3 | -5611.00 USD | -100.17% |
| 2006 Q2 | 3.35 Million USD | 237.31% |
| 2006 FY | -2.41 Million USD | 95.42% |
| 2005 Q3 | -2.77 Million USD | 79.89% |
| 2005 Q1 | -12.36 Million USD | -72.99% |
| 2005 Q2 | -13.78 Million USD | -11.52% |
| 2005 FY | -52.61 Million USD | -171.77% |
| 2005 Q4 | -20.79 Million USD | -649.75% |
| 2004 Q2 | -2.43 Million USD | 67.69% |
| 2004 Q1 | -7.54 Million USD | -199.04% |
| 2004 Q3 | -2.23 Million USD | 8.43% |
| 2004 Q4 | -7.14 Million USD | -220.38% |
| 2004 FY | -19.35 Million USD | -461.9% |
| 2003 Q1 | -147.19 Thousand USD | 0.0% |
| 2003 Q3 | -325.88 Thousand USD | 24.74% |
| 2003 Q4 | -2.52 Million USD | -673.98% |
| 2003 FY | -3.44 Million USD | -40044.07% |
| 2003 Q2 | -432.98 Thousand USD | -194.16% |
| 2002 Q1 | -210.00 USD | 97.43% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 100.0% |
| 2002 FY | -8582.00 USD | -50.03% |
| 2001 Q3 | -105.00 USD | 0.0% |
| 2001 Q1 | -5159.00 USD | -2766.11% |
| 2001 FY | -5720.00 USD | -70.54% |
| 2001 Q4 | -8162.00 USD | -7673.33% |
| 2001 Q2 | -105.00 USD | 97.96% |
| 2000 Q4 | -180.00 USD | -13.21% |
| 2000 FY | -3354.00 USD | -112.01% |
| 2000 Q2 | -222.00 USD | 92.69% |
| 2000 Q3 | -159.00 USD | 28.38% |
| 2000 Q1 | -3037.00 USD | 0.0% |
| 1999 Q2 | -159.00 USD | 0.0% |
| 1999 Q3 | -158.00 USD | 0.63% |
| 1999 Q4 | - USD | 100.0% |
| 1999 FY | -1582.00 USD | -149.53% |
| 1998 FY | -634.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 95.722% |
| Prenetics Global Limited | -62.72 Million USD | 84.142% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -542.575% |
| CareDx, Inc | -190.28 Million USD | 94.773% |
| Exact Sciences Corporation | -204.14 Million USD | 95.128% |
| Exagen Inc. | -23.68 Million USD | 58.01% |
| Inotiv, Inc. | -105.14 Million USD | 90.539% |
| Guardant Health, Inc. | -479.44 Million USD | 97.925% |
| Biodesix, Inc. | -52.14 Million USD | 80.925% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -278.353% |
| Precipio, Inc. | -5.85 Million USD | -69.948% |
| iSpecimen Inc. | -11.09 Million USD | 10.383% |
| Natera, Inc. | -434.8 Million USD | 97.712% |
| Aspira Women's Health Inc. | -16.69 Million USD | 40.401% |
| Standard BioTools Inc. | -74.65 Million USD | 86.676% |
| 23andMe Holding Co. | -666.7 Million USD | 98.508% |
| Castle Biosciences, Inc. | -57.46 Million USD | 82.691% |
| Personalis, Inc. | -108.29 Million USD | 90.815% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 88.758% |
| OpGen, Inc. | -32.66 Million USD | 69.552% |
| T2 Biosystems, Inc. | -50.07 Million USD | 80.136% |
| Myriad Genetics, Inc. | -112 Million USD | 91.119% |
| ICON Public Limited Company | 612.33 Million USD | 101.624% |
| NeoGenomics, Inc. | -87.96 Million USD | 88.692% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -542.575% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 101.177% |
| RadNet, Inc. | 3.04 Million USD | 426.776% |
| MDxHealth SA | -43.1 Million USD | 76.921% |
| Psychemedics Corporation | -4.15 Million USD | -139.457% |
| Illumina, Inc. | -1.16 Billion USD | 99.143% |
| Check-Cap Ltd. | -17.56 Million USD | 43.38% |
| Twist Bioscience Corporation | -208.72 Million USD | 95.234% |
| DarioHealth Corp. | -59.42 Million USD | 83.262% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 94.073% |
| Sera Prognostics, Inc. | -36.24 Million USD | 72.554% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | 1.125% |
| OPKO Health, Inc. | -188.86 Million USD | 94.733% |
| Medpace Holdings, Inc. | 282.81 Million USD | 103.517% |
| Neogen Corporation | -9.42 Million USD | -5.584% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 2.065% |
| Prenetics Global Limited | -62.72 Million USD | 84.142% |
| Mainz Biomed B.V. | -26.29 Million USD | 62.172% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -25.325% |
| Trinity Biotech plc | -24.01 Million USD | 58.585% |
| Neuronetics, Inc. | -30.18 Million USD | 67.051% |
| Sotera Health Company | 51.37 Million USD | 119.361% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -25.325% |